<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437656</url>
  </required_header>
  <id_info>
    <org_study_id>METCAP-1404</org_study_id>
    <secondary_id>2014-003687-20</secondary_id>
    <nct_id>NCT02437656</nct_id>
  </id_info>
  <brief_title>Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).</brief_title>
  <official_title>Phase II Study Evaluating the Efficacy of the Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin is an oral antidiabetic of the biguanide class derived from galega officinalis.&#xD;
      Historical cohort of patients with diabetes have shown that diabetics on Metformin had a&#xD;
      better chance of survival than diabetics not on Metformin. These observations have led to in&#xD;
      vitro studies of metformin on cancer cells. It was thus demonstrated that Metformin has&#xD;
      anti-proliferative properties.&#xD;
&#xD;
      The aim of our study is to evaluate the efficacy of metformin in combination with neoadjuvant&#xD;
      radiochemotherapy in the treatment of locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the trial and having signed their consent to participate will undergo a&#xD;
      dosimetric scan at baseline. 48 hours later (minimum), a Metformin therapy will be started at&#xD;
      a dosage of 850 mg 2 times / day ( = 1700 mg / day). Seven days later (minimum) and up to 48&#xD;
      hours before surgery, the dosage of Metformin will be increased to 850 mg 3 times / day ( =&#xD;
      2550 mg / day). This very same day (J10), patients will start a radiochemotherapy. For 5&#xD;
      weeks, 5 days out of 7, patients will receive 800 mg/m² of Capecitabine 2 times / day (on&#xD;
      morning and evening) ( = 1600 mg / m² / day) and a 3D irradiation or an Intensity-Modulated&#xD;
      Radiation Therapy (IMRT) of a total dose of 50 Gy (5 sessions of 2 Gy per week). 6 to 8 weeks&#xD;
      after completion of the chemoradiotherapy, surgery will be scheduled. It will consist of a&#xD;
      tumor resection with total resection of the meso rectum.&#xD;
&#xD;
      Prior to the start of treatment, patients will have a clinical and a paraclinical examination&#xD;
      and will undergo a laboratory examination. Once a week during the radiochemotherapy, patients&#xD;
      will have a clinical examination and will undergo a laboratory examination. Three weeks after&#xD;
      the end of the radiochemotherapy, patients will have a clinical examination. Before surgery,&#xD;
      patients will have a clinical and a paraclinical examination. Finally, at the end of the&#xD;
      study, patients will have a clinical examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity will be assessed according to NCI-CTCAE v4.0. Grades ≥ 3 related to metformin will be collected by the clinician.</measure>
    <time_frame>up to 30 days after the end of the treatments (metformin and radiochemotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter preservation rate and downstaging rate</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>J1 : dosimetric scan&#xD;
J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)&#xD;
J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy&#xD;
J44 : end of the radiochemotherapy&#xD;
Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>J3 - J10 (7 days minimum) : 850 mg 2 times / day&#xD;
J10 - 48h before surgery : 850 mg 3 times / day</description>
    <arm_group_label>Metformin treatment</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Diabamyl</other_name>
    <other_name>Stagid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with an adenocarcinoma of the low or middle rectum.&#xD;
&#xD;
          2. T3 or T4 stage (T evaluated by MRI and / or echo-endoscopy).&#xD;
&#xD;
          3. Absence of distant metastasis.&#xD;
&#xD;
          4. Patient requiring a radiochemotherapy.&#xD;
&#xD;
          5. Correct hematological conditions : Neutrophils ≥ 1500 G / L, platelets ≥ 100 000 G /&#xD;
             L.&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. Performance status (WHO) ≤ 2&#xD;
&#xD;
          8. Lactatemia ≤ Higher standard of the sampling laboratory.&#xD;
&#xD;
          9. For women of childbearing age, a contraceptive method is mandatory for the entire&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other histologies such as squamous cell carcinoma, neuroendocrine tumors, melanomas,&#xD;
             etc.&#xD;
&#xD;
          2. History of lactic acidosis.&#xD;
&#xD;
          3. Any diabetes (According to the WHO definition : fasting plasma glucose (FPG) &gt; 1.26 g&#xD;
             / L-1).&#xD;
&#xD;
          4. Ongoing antidiabetic treatment such as&#xD;
&#xD;
               -  Biguanides, hypoglycemic sulfamides, glinides, GLP-1 analogue, gliptins,&#xD;
                  alpha-glucosidase inhibitors&#xD;
&#xD;
               -  Insulin or insulin analogues&#xD;
&#xD;
          5. Hypersensitivity to capecitabine or to any of the excipients or to fluorouracil.&#xD;
&#xD;
          6. History of severe and unexpected reactions to a fluoropyrimidine therapy.&#xD;
&#xD;
          7. Patient with known deficiency to the dihydropyrimidine dehydrogenase (DPD).&#xD;
&#xD;
          8. Hypersensitivity to metformin or to any of the excipients.&#xD;
&#xD;
          9. Renal failure or impaired renal function (creatinine clearance &lt; 60 ml / min).&#xD;
&#xD;
         10. Severe infection.&#xD;
&#xD;
         11. Acute or chronic disease which may cause tissue hypoxia such as heart or respiratory&#xD;
             failure or recent myocardial infarction (&lt; 6 months).&#xD;
&#xD;
         12. Hepatic insufficiency, acute alcohol intoxication, alcoholism.&#xD;
&#xD;
         13. Psychiatric inability to give consent.&#xD;
&#xD;
         14. Contraindication to radiation therapy and/or chemotherapy.&#xD;
&#xD;
         15. Treatment with sorivudine or its chemically related analogues, such as brivudine.&#xD;
&#xD;
         16. Patient under tutorship or guardianship.&#xD;
&#xD;
         17. Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier MIRABEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Marie Curie</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pierre Curie</name>
      <address>
        <city>Beuvry</city>
        <zip>62880</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léonard de Vinci - SARL du pont Saint Vaast</name>
      <address>
        <city>Douai</city>
        <zip>59500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut André Dutreix</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Bois - Centre Bourgogne</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Galilée - Hôpital Privé La Louvière</name>
      <address>
        <city>Lille</city>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Gray</name>
      <address>
        <city>Maubeuge</city>
        <zip>59600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Joliot-Curie</name>
      <address>
        <city>St Martin-Boulogne</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Dentellières</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Metformin</keyword>
  <keyword>Rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

